Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update

Wolff, Antonio C.; Somerfield, Mark R.; Dowsett, Mitch; Hammond, M. Elizabeth H.; Hayes, Daniel F.; McShane, Lisa M.; Saphner, Thomas J.; Spears, Patricia A.; Allison, Kimberly H.

doi:10.1200/jco.22.02864

reviewJournal of Clinical OncologyJun 7, 2023Closed access

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update

ACAntonio C. Wolff MRMark R. Somerfield MDMitch Dowsett MEM. Elizabeth H. Hammond DFDaniel F. Hayes

Sidney Kimmel Comprehensive Cancer Center · American Society of Clinical Oncology · +8 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Methods

An Update Panel conducted a systematic literature review to identify signals for updating recommendations.

Results

The search identified 173 abstracts. Of five potential publications reviewed, none constituted a signal for revising existing recommendations. RECOMMENDATIONS: The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.

Citation impact

554

total citations

FWCI: 119.72
Percentile: 100%
References: 15

Citations per year

Authors

9

Topics & keywords

Topics

Keywords

Trastuzumab
Medicine
Breast cancer
Oncology
Human Epidermal Growth Factor Receptor 2
Immunohistochemistry
Cancer
Internal medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.